Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Accounts Payables: 2021-2024

Historic Accounts Payables for ARS Pharmaceuticals (SPRY) over the last 4 years, with Dec 2024 value amounting to $22.8 million.

  • ARS Pharmaceuticals' Accounts Payables rose 201.24% to $49.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.8 million, marking a year-over-year increase of 201.24%. This contributed to the annual value of $22.8 million for FY2024, which is 960.40% up from last year.
  • ARS Pharmaceuticals' Accounts Payables amounted to $22.8 million in FY2024, which was up 960.40% from $2.2 million recorded in FY2023.
  • In the past 5 years, ARS Pharmaceuticals' Accounts Payables ranged from a high of $22.8 million in FY2024 and a low of $2.2 million during FY2023.
  • Moreover, its 3-year median value for Accounts Payables was $4.9 million (2022), whereas its average is $10.0 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first plummeted by 56.32% in 2023, then spiked by 960.40% in 2024.
  • Yearly analysis of 4 years shows ARS Pharmaceuticals' Accounts Payables stood at $3.1 million in 2021, then soared by 58.71% to $4.9 million in 2022, then crashed by 56.32% to $2.2 million in 2023, then surged by 960.40% to $22.8 million in 2024.